The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Geoff Robins/The Globe and Mail
A tiny London, Ont., medical device company hoping to change how diabetes is treated has had a wild ride of late. Last Friday, stock in Sernova Corp. shot up 65 per cent on the TSX Venture Exchange, then nearly doubled on Monday, closing at $2.42 a share. At its peak, Sernova had a market capitalization of $630-million, making it one of Canada’s 15 most valuable publicly traded life sciences companies.